Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel coronavirus, causes coronavirus disease 2019 (COVID-19), an infectious disease that shows the upper respiratory system symptoms such as fever, cough, tiredness, loss of taste or smell, and sore throat. SARS-CoV-2 is transmitted mainly by respiratory fluids, especially aerosol particles from people infected by this virus [
1- Wang CC
- Prather KA
- Sznitman J
- Jimenez JL
- Lakdawala SS
- Tufekci Z
- et al.
Airborne transmission of respiratory viruses.
,
2- Meyerowitz EA
- Richterman A
- Gandhi RT
- Sax PE.
Transmission of SARS-CoV-2: a review of viral, host, and environmental factors.
,
3- Greenhalgh T
- Jimenez JL
- Prather KA
- Tufekci Z
- Fisman D
- Schooley R.
Ten scientific reasons in support of airborne transmission of SARS-CoV-2.
]. The middle ear and mastoid connect to the nasopharynx via the Eustachian tube, and the middle ear mucosa is anatomically classified as a respiratory epithelium [
[4]Histologic studies of the normal mucosa in the middle ear, mastoid cavities and Eustachian tube.
]. Therefore, the middle ear and mastoid are considered part of the upper airway. Virological studies revealed that common respiratory viruses, such as rhinovirus, respiratory syncytial (RS) virus, or coronavirus, were detected from a middle ear specimen in 48% of children with acute otitis media (AOM) and 30% of children with otitis media with effusion (OME), respectively [
[5]- Pitkäranta A
- Jero J
- Arruda E
- Virolainen A
- Hayden FG.
Polymerase chain reaction–based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion.
,
[6]- Pitkäranta A
- Virolainen A
- Jero J
- Arruda E
- Hayden FG.
Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction.
. Among these viruses, coronavirus was identified in 8% and 3% of the AOM and OME populations, respectively [
[5]- Pitkäranta A
- Jero J
- Arruda E
- Virolainen A
- Hayden FG.
Polymerase chain reaction–based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion.
,
[6]- Pitkäranta A
- Virolainen A
- Jero J
- Arruda E
- Hayden FG.
Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction.
. Considering that SARS-CoV-2 belongs to the family Coronaviridae [
[7]Coronaviridae Study Group of the International Committee on Taxonomy of Viruses
The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.
], it is plausible that COVID-19 patients have SARS-CoV-2 virus in the middle ear and mastoid. Otology guidelines recommended postponing non-urgent mastoid surgeries during the COVID-19 pandemic [
[8]- Givi B
- Schiff BA
- Chinn SB
- Clayburgh D
- Iyer NG
- Jalisi S
- et al.
Safety recommendations for evaluation and surgery of the head and neck during the COVID-19 pandemic.
,
because mastoid drilling by powered instruments induces significant bone and other tissue aerosols [
[10]- Jewett DL
- Heinsohn P
- Bennett C
- Rosen A
- Neuilly C.
Blood-containing aerosols generated by surgical techniques a possible infectious hazard.
], which may contain a viable virus when the SARS-CoV-2 virus infects the patients. Autopsy studies of deceased COVID-19 patients proved the SARS-CoV-2 virus in the middle ear [
[11]- Heikkinen T
- Thint M
- Chonmaitree T.
Prevalence of various respiratory viruses in the middle ear during acute otitis media.
,
[12]- Jeican II
- Aluaș M
- Lazăr M
- Barbu-Tudoran L
- Gheban D
- Inișca P
- et al.
Evidence of SARS-CoV-2 virus in the middle ear of deceased COVID-19 patients.
and mastoid [
[13]- Frazier KM
- Hooper JE
- Mostafa HH
- Stewart CM.
SARS-CoV-2 virus isolated from the mastoid and middle ear: implications for COVID-19 precautions during ear surgery.
], indicating that this recommendation is reasonable. The guidelines also recommend that if ear surgery is required during a COVID-19 pandemic, a negative test for COVID-19 should be confirmed before surgery [
[8]- Givi B
- Schiff BA
- Chinn SB
- Clayburgh D
- Iyer NG
- Jalisi S
- et al.
Safety recommendations for evaluation and surgery of the head and neck during the COVID-19 pandemic.
,
,
. Reverse transcription PCR (RT-PCR) using nasopharyngeal or oropharyngeal swabs are the gold standards for identifying the SARS-CoV-2 in the upper respiratory system [
[15]- Tsang NNY
- So HC
- Ng KY
- Cowling BJ
- Leung GM
- Ip DKM.
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis.
,
[16]Organization WH. Laboratory testing for coronavirus disease (COVID-19) in suspected human cases: interim guidance, 19 March 2020. Organization WH, editor: World Health Organization; 2020.
. It should be noted that in a previous large cohort study, 2-3% of patients with AOM tested positive for coronavirus in PCR of middle ear specimens, but no coronavirus was detected in concurrent PCR of nasopharyngeal specimens [
[6]- Pitkäranta A
- Virolainen A
- Jero J
- Arruda E
- Hayden FG.
Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction.
,
[17]- Nokso-Koivisto J
- Pitkäranta A
- Blomqvist S
- Kilpi T
- Hovi T.
Respiratory coronavirus infections in children younger than two years of age.
. Considering that coronaviruses are detected in middle ear specimens in 8% of patients with AOM [
[6]- Pitkäranta A
- Virolainen A
- Jero J
- Arruda E
- Hayden FG.
Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction.
], as mentioned above, these studies imply that PCR testing of the nasopharyngeal swab alone may not be sufficient to prove the absence of coronaviruses, including the SARS-CoV-2, in the middle ear and mastoid cavity.
This study aimed to elucidate the probability of a positive SARS-CoV-2 result in PCR test using the middle ear or mastoid specimens in otologic surgery patients in whom SARS-CoV-2 was not detected by preoperative PCR test using nasopharyngeal swabs. We included otologic surgery patients who met the following criteria: (1) no COVID-19 symptom nor close contact with a confirmed COVID-19 patient for two weeks before ear surgery and (2) negative SARS-CoV-2 PCR test of nasopharyngeal swabs on the day or a couple of days before surgery. Our results will be valuable in establishing guidelines for safe otologic surgery if the COVID-19 pandemic persists for a long time.
1.1 Participants and methods
We conducted a prospective, multicenter clinical study involving three tertiary hospitals from different regions in Japan. Among the patients who underwent otologic surgery under general anesthesia at our hospitals between April 2020 and December 2021, we recruited 228 patients who gave written consent to this study by themselves or their guardians. This study period was determined because COVID-19 outbreaks, including those in healthcare institutions, have started since January 2020 in Japan. Three of 228 patients (1.3%) had suffered from COVID-19 more than one month prior to the surgery. Before hospital admission for otologic surgery, all participants were clinically and laboratory-confirmed to be negative for COVID-19. That is, we performed SARS-CoV-2 real-time RT-PCR testing using a nasopharyngeal swab [
[18]- Ito J
- Seo R
- Kawakami D
- Matsuoka Y
- Ouchi K
- Nonami S
- et al.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in Kobe, Japan: a single-center, retrospective, observational study.
] on the admission day or 1-2 business days before admission, in addition to confirming the absence of any symptoms suggesting COVID-19 nor close contact with a confirmed COVID-19 patient in the two weeks prior to admission. The N2 primer-probe set defined by the CDC was used in our SARS-CoV-2 real-time RT-PCR testing [
]. In one of our hospitals (Kobe City Medical Center General Hospital (KCGH)), during the same period as this study, all patients scheduled for surgery in any departments underwent the same examinations for COVID-19 symptoms and SARS-CoV-2 PCR of nasopharyngeal swab before their hospital admission (
Fig. 1A). Except for patients immediately after COVID-19 recovery, 17 out of the 14,266 scheduled surgical patients (0.12%) had no symptoms suggesting COVID-19 but showed positive for the SARS-CoV-2 PCR test. These 17 positive patients were scheduled non-otologic surgeries, and all surgeries except for urgent ones were postponed. The temporal changes in the positive rate of the pre-admission PCR test are closely related to waves of COVID-19 in Japan [
] (
Figs. 1B and C). One of these 17 PCR-positive patients developed COVID-19 soon after the test, and four complained of minor symptoms, such as rhinorrhea, fatigue, or sore throat. The remaining 12 patients had no symptoms throughout two weeks after the PCR.
The 251 ears from the 228 participants underwent otologic surgeries in our hospitals. All medical staff in the operation room used the standard personal protective equipment against aerosol-generating interventional procedures, including an N95 mask, goggle or face shield, gown, and double gloves [
[21]- Couloigner V
- Schmerber S
- Nicollas R
- Coste A
- Barry B
- Makeieff M
- et al.
COVID-19 and ENT surgery.
]. In some cases, standard surgical masks were used due to an insufficient supply of N95 masks. We investigated types of surgeries, the age at operation, with and without mastoidectomy, and the degree of inflammation of the middle ear and mastoid cavity based on the intraoperative findings. In each otologic surgery, we collected a PCR test specimen from the tympanic or mastoid cavity. We selected PCR specimens according to previous studies [
[12]- Jeican II
- Aluaș M
- Lazăr M
- Barbu-Tudoran L
- Gheban D
- Inișca P
- et al.
Evidence of SARS-CoV-2 virus in the middle ear of deceased COVID-19 patients.
,
[13]- Frazier KM
- Hooper JE
- Mostafa HH
- Stewart CM.
SARS-CoV-2 virus isolated from the mastoid and middle ear: implications for COVID-19 precautions during ear surgery.
. Mastoidectomy using a powered instrument is considered the highest risk of aerosol production. Therefore, when mastoidectomy was performed, otologic specimens were collected from the mastoid. Mucosa and granulation around the aditus of the antrum were our first choice, and if these were not available, the mucosa and granulation in the mastoid air cells were usually collected. A mixture of bone dust and mucosa fragments after drilling was obtained as otologic specimens in a few cases. The mucosa, granulation, or fluid in the tympanic cavity was collected as PCR specimens in patients without mastoidectomy. The method for the SARS-CoV-2 PCR test of these otologic specimens was the same as for the PCR test of nasopharyngeal swabs. The PCR tests were performed in the same institute where the specimens were collected.
At Kyoto University, the otologic specimens were soaked in RNA stabilization solution (RNAlaterⓇ, Invitrogen, Carlsbad, USA) immediately after their collection and stored at 4℃ up to 4 days before RNA purification. In the other two institutes (Hiroshima University and KCGH), the collected otologic specimens were stored at 4℃ in normal saline or in a sealed sterile container to prevent drying up to 24 hours before RNA purification. Viral RNA was purified by NucleoSpinⓇ RNA Virus (Takara Bio Inc., Shiga, Japan) at Kyoto University, Takara SARS-CoV-2 Direct PCR detection kit (Takara Bio Inc., Shiga, Japan) at Hiroshima University, and Maxwell RSC Viral Total Nucleic Acid Purification Kit (Promega, Madison, USA) at KCGH. Tissue specimens such as mucosa and granulation were minced and incubated in lysis buffer containing proteinase K at 56 ℃ for 10-30 minutes at the first step of the RNA purification, equal to or longer than that for the nasal swab. Then, RT-PCR products amplified by One Step PrimeScript™ III RT-qPCR Mix (Takara Bio Inc., Shiga, Japan) with the N2 primer-probe set were quantified by Bio-Rad CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, USA) at Kyoto University and KCGH. At Hiroshima University, Takara SARS-CoV-2 Direct PCR detection kit with the N2 primer-probe set was used for RT-PCR, and the amplified PCR products were quantified by Thermal Cycler DiceⓇ Real Time System III (Takara Bio Inc., Shiga, Japan). The cut-off cycle threshold value for real-time RT-PCR was determined as 40 cycles in all institutes.
The ethics committees of each institute approved the study protocols (zn200719 for KCGH, E-2105 for Hiroshima University, and R2600 for Kyoto University).